Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. - Wikidata - awgldk - TriplyDB

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q37919866

about

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Considerations regarding adherence of anti-osteoporosis therapy.Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

P2860

Q33400612-44962DE9-CD77-4C48-9468-744F0C348EFC Q34573847-2F0DA923-31E6-441C-B6D3-AB071FE729C5 Q36844535-FFF4E1D7-8D28-474D-B73D-78E0706E82E8 Q37963977-C995AF93-C28A-482A-8F20-E33459972AFC Q37970113-EED972B3-32A8-4AE6-86B1-BB85F02D5A8C Q37979273-65F3094F-0C0B-4B89-B524-06782E599088 Q38040848-677FF719-0BBE-4F84-ACB2-33A2CA890068 Q38051449-F8A1897C-A616-4869-8915-1EA82207220B Q38074913-89B5EB4E-E11D-42DF-9A71-E40AF2BE4B90 Q38076077-36251BB3-EB55-4DB3-8D09-8F7D17678CCD Q38078288-66039B34-57B9-4921-97CD-D1878F989774 Q38080911-258CB251-8B59-419D-BDD7-3F813E61B960 Q38091324-E5275786-0698-44AD-A63E-E97F5F606F76 Q38097338-C9F5877C-3E6C-437D-B253-1A02D508D2B1 Q38098104-3583D3A0-EBCE-48AE-97A0-26627AEF8B7F Q38098483-55DC2D62-544F-438F-B039-FEBF0A9758C6 Q38098484-D208811B-0193-465E-BD1E-E1A2F123F186 Q38101892-FDC043F2-AEE0-4249-8A34-A2485C1FFBDA Q38133381-2048D518-FFEA-41B7-A9DD-7D7DC9F92758 Q38149091-094A5BFB-54A6-47BA-82A4-E2E7E6815EEB Q38294766-DCCAD0DC-C4BD-445A-961D-C03A7FF88927 Q44065014-0B76292D-3395-4D73-8EB2-B1FE77F038CE Q46933439-83D4CD75-6C18-4BC4-A487-3E3D60B4DA32

P2860

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q37919866

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Denosumab for the prevention o ...... E single technology appraisal.

@en

Denosumab for the prevention o ...... E single technology appraisal.

@nl

type

label

Denosumab for the prevention o ...... E single technology appraisal.

@en

Denosumab for the prevention o ...... E single technology appraisal.

@nl

prefLabel

Denosumab for the prevention o ...... E single technology appraisal.

@en

Denosumab for the prevention o ...... E single technology appraisal.

@nl

P1433

Q37919866-53DDDA82-DA89-48FD-B2DA-389D46AECE55

P1476

Q37919866-2C160F69-F65A-4685-A505-83AC96681D38

P2093

Q37919866-1226DF2D-42ED-47E4-BECF-A2DAA3D73B09

Q37919866-27335F1D-19FF-49CA-B20F-A609C9F941EF

Q37919866-3235E89A-8B9C-456E-A694-337B63A456B1

Q37919866-8A39BE64-5A47-4EF7-B555-AE7943ABCA02

Q37919866-8C5DC9C2-5388-4CEE-BCC4-9315AB11A800

P2860

Q37919866-2901C52F-754B-47FB-8028-E67E71153531

Q37919866-37F52C2A-2658-44B6-A43C-66ABA32B8F53

Q37919866-530EDEE1-1EFE-4A5C-B9A6-CD257E0489E8

Q37919866-5C2E95FC-891D-4E5D-AAA4-8CF56E99D19C

Q37919866-71C6DD2E-BB43-4AD6-9666-0A78ED0A30EA

Q37919866-9A548038-A129-4F9A-AF72-86FAE971B011

Q37919866-B0FBE7EB-D174-4E44-AAC6-24EC482BCE39

Q37919866-C441CEC4-1A03-4E02-B778-9B8CE4ED232D

Q37919866-FEA1AB98-6260-45D9-8615-68AF03966824

P2888

Q37919866-7BB25FAA-8781-4D74-ABC7-58DB922DC12E

P304

Q37919866-0B0D87DD-414D-4F5D-A555-D2BE37863026

P31

Q37919866-5CDE41E5-92E2-42B1-8329-27F86F349031

P356

Q37919866-CF20CE35-B431-472B-A00D-6E11BCE01128

P433

Q37919866-6B6B3C76-B85C-4B7E-805F-12540BC922E0

P478

Q37919866-3BACA1D8-9419-49B3-8969-24C2C5ADD551

P50

Q37919866-B42FBC7B-9943-42AE-B5B2-127000F833E7

P577

Q37919866-11FF19F1-9359-453B-853A-8A42162536ED

P6179

Q37919866-F837F366-B59B-4764-92E8-01336A51E3A4

P698

Q37919866-49C6B9E4-AB76-4ECF-BA0E-4BBC5EC228E5

P921

Q37919866-E7527E54-FBF9-4597-A1E3-B52B4C5AC744

P356

11589310-000000000-00000

P1433

PharmacoEconomics

P1476

Denosumab for the prevention o ...... CE single technology appraisal

@en

P2093

Graham Scotland

http://www.w3.org/2001/XMLSchema#string

Norman Waugh

http://www.w3.org/2001/XMLSchema#string

Pamela Royle

http://www.w3.org/2001/XMLSchema#string

Paul McNamee

http://www.w3.org/2001/XMLSchema#string

Rob Henderson

http://www.w3.org/2001/XMLSchema#string

P2860

FRAX and the assessment of fracture probability in men and women from the UK

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.

P2888

11589310-000000000-00000

P304

951-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11589310-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Rosemary Hollick

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042194097

http://www.w3.org/2001/XMLSchema#string

P698

21854080

http://www.w3.org/2001/XMLSchema#string

P921